Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706) - Concepedia

Concepedia

Publication | Closed Access

Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)

116

Citations

48

References

2021

Year

Hongyun Zhao, Wenxiu Yao, Xuhong Min, Kangsheng Gu, Guohua Yu, Zhonghan Zhang, Jiuwei Cui, Liyun Miao, Li Zhang, Xia Yuan,

Journal of Thoracic Oncology

Apatinib Plus GefitinibMedicineAdvanced Egfr-mutant NsclcFirst-line TreatmentCell BiologyCancer TreatmentCancer GeneticsOncologyRadiation OncologyNovel TherapyMolecular Oncology

References

	Year	Citations

Page 1

Page 1